Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | CTSV | O60911 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8501957 | 0.95 | PARP1 (0.60) | PARP1CTSVCTSLHSD17B10KDM4E | |
| Alcohol SCHEMBL27310243 | 0.91 | PARP1 (0.56) | PARP1CTSVCTSLHSD17B10KDM4E | |
| SCHEMBL9179087 | 0.89 | RAB9A (0.50) | PARP1CTSVCTSLHSD17B10KDM4E | |
| SCHEMBL9384223 | 0.82 | DDAH1 (0.58) | CTSVCTSLKDM4EALDH1A1HPGD | |
| SCHEMBL19953289 | 0.78 | TSHR (0.51) | PARP1KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL7197832 | 0.78 | GPR84 (0.43) | PARP1POLBGPR84 | |
| SCHEMBL30823858 | 0.78 | POLB (0.83) | PARP1ALDH1A1RAB9ANPC1POLB | |
| SCHEMBL170803 | 0.78 | POLB (0.83) | PARP1ALDH1A1RAB9ANPC1POLB | |
| SCHEMBL9705784 | 0.77 | KDM4C (0.51) | PARP1 | |
| SCHEMBL9376294 | 0.77 | KMT2A (0.54) | PARP1HSD17B10POLBTSHRGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486887-A | Polycyclic pyrimidine-4-ketone compound and preparation method and application thereof | 昆明学院 | 2024-02-02 | — | — | CN | disclosed |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2021-09-30 | — | — | US | disclosed |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2020-06-04 | — | — | US | disclosed |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2019-03-21 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2018046933-A1 | TANKYRASE INHIBITORS | UNIVERSITY OF BATH (GB) | 2018-03-15 | — | — | WO | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-9095596-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-04 | — | — | US | disclosed |
| US-9045437-B2 | 2-aryl-4-quinazolinones and their pharmaceutical compositions | CHINA MEDICAL UNIVERSITY (TW) | 2015-06-02 | — | — | US | disclosed |
| WO-2004069195-A2 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS OF THE AIRWAYS | IVAX CORPORATION (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | disclosed |
| US-6534511-B1 | The use of certain 6-arylpyrazolo(3,4-d)pyrimidin-4-ones, 2 arylquinazolin-4-ones, 2-arylpurin-6-ones and 2-arylpyrido(3,2- d)pyrimidin-4-ones, or a pharmaceutically acceptable salt thereof, forsexual disorders | PFIZER INC. | 2003-03-18 | — | — | US | disclosed |
| EP-0793498-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 2002-12-11 | — | — | EP | disclosed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | disclosed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | disclosed |
| EP-0793498-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016657-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
| US-4431440-A | 2-/4-METHYLPHENYL/-4-3H-QUINAZOLINES AS HERBICIDES AND PLANT GROWTH REGULATORS; CEREALS | AMERICAN CYANAMID COMPANY (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0058822-A1 | Method to alter or control the development and/or life cycle of various plant species | AMERICAN CYANAMID COMPANY (US) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | PARP1 2219/4885CTSV 897/4885CTSL 3231/4885 |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | PARP1 2220/4885CTSV 879/4885CTSL 3201/4885 |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | PARP1 2220/4885CTSV 879/4885CTSL 3201/4885 |
| US-20040152694-A1 | Methods and compositions for treating inflammatory disorders of the airways | LTB4R2, LTB4R, LTC4S | PARP1 2480/4885CTSV 916/4885CTSL 747/4885 |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | PARP1 2220/4885CTSV 879/4885CTSL 3201/4885 |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | NFKBIA, NFRKB, TFEB | PARP1 2220/4885CTSV 879/4885CTSL 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.